| 29093181 |
A precision therapy against cancers driven by KIT/PDGFRA mutations
Evans, EK,
Gardino, AK,
Kim, JL,
Hodous, BL,
Shutes, A,
Davis, A,
Zhu, XJ,
Schmidt-Kittler, O,
Wilson, D,
Wilson, K,
DiPietro, L,
Zhang, Y,
Brooijmans, N,
LaBranche, TP,
Wozniak, A,
Gebreyohannes, YK,
Schöffski, P,
Heinrich, MC,
Deangelo, DJ,
Miller, S,
Wolf, B,
Kohl, N,
Guzi, T,
Lydon, N,
Boral, A,
Lengauer, C
|
Sci Transl Med |
2017 |
| 31085175 |
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Smith, BD,
Kaufman, MD,
Lu, WP,
Gupta, A,
Leary, CB,
Wise, SC,
Rutkoski, TJ,
Ahn, YM,
Al-Ani, G,
Bulfer, SL,
Caldwell, TM,
Chun, L,
Ensinger, CL,
Hood, MM,
McKinley, A,
Patt, WC,
Ruiz-Soto, R,
Su, Y,
Telikepalli, H,
Town, A,
Turner, BA,
Vogeti, L,
Vogeti, S,
Yates, K,
Janku, F,
Abdul Razak, AR,
Rosen, O,
Heinrich, MC,
Flynn, DL
|
Cancer Cell |
2019 |
